Aficamten for teens with obstructive hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new medicine called aficamten for teenagers with a heart condition that makes the heart muscle too thick and blocks blood flow. The medicine may help make the heart pump more easily and improve symptoms like shortness of breath or chest pain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old.
- You weigh at least 45 kg (99 lbs), or at least 35 kg if you are in a later group.
- You have a type of thickened heart muscle that runs in families or is caused by a gene change.
- Your heart's pumping strength is normal or better, and there is a significant blockage during a Valsalva maneuver (forceful breathing out).
- You have had symptoms like shortness of breath, chest pain, or feeling tired, even with mild activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This trial combines a new heart medication (mavacamten) with a procedure called radiofrequency ablation to treat a condition where the heart muscle thickens and blocks blood flow. It is for people who still have symptoms despite standard care.
Hear when a new Pediatric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.